Citadel Advisors
ABVC icon

Citadel Advisors’s ABVC BioPharma ABVC Stock Holding History

Citadel Advisors’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-55,543
Closed -$118K – 12864
2025
Q4 		$118K Buy
55,543
+39,879
+255% +$107K ﹤0.01% 11506
2025
Q3 		$47.6K Buy
+15,664
New +$48.1K ﹤0.01% 12233
2025
Q1 		– Sell
-40,743
Closed -$24K – 14366
2024
Q4 		$24K Buy
+40,743
New +$22.7K ﹤0.01% 13053
2024
Q3 		– Sell
-25,212
Closed -$19.5K – 14122
2024
Q2 		$19.5K Buy
+25,212
New +$25.9K ﹤0.01% 12666
2024
Q1 		– Sell
-27,158
Closed -$31.5K – 14466
2023
Q4 		$31.5K Buy
27,158
+11,567
+74% +$13.6K ﹤0.01% 12226
2023
Q3 		$16.2K Buy
+15,591
New +$37.7K ﹤0.01% 12786
2022
Q4 		– Sell
-1,261
Closed -$11K – 14817
2022
Q3 		$11K Buy
+1,261
New +$10.6K ﹤0.01% 12248

Other funds holding ABVC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Citadel Advisors's ABVC Position: Q1 2026 in Review

Citadel Advisors sold out of ABVC BioPharma (ABVC) in Q1 2026, closing a stake of 55,543 shares — an estimated $118K sold.

Citadel Advisors first reported a position in ABVC in Q3 2022 and held it in 7 quarters. The position peaked at $118K in Q4 2025. 13 funds tracked by Wall St. Rank hold ABVC as of Q1 2026.

  • Citadel Advisors reported no remaining ABVC BioPharma position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 55,543 ABVC BioPharma shares in Q1 2026, an estimated $118K.
  • Citadel Advisors first reported a position in ABVC BioPharma in Q3 2022 and held it in 7 quarters.
  • Citadel Advisors's ABVC BioPharma position peaked at $118K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held ABVC BioPharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.